Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
Ahn JS, Kim T, Jung SH, Ahn SY, Jung SY, Song GY, Kim M, Yang DH, Lee JJ, Choi S, Lee JY, Park SK, Moon JH, Lee HY, Kim KH, Cai Y, Yi SY, Novitzky-Basso I, Zhang Z, Kim HJ, Kim DDH. Ahn JS, et al. Bone Marrow Transplant. 2021 May;56(5):1159-1170. doi: 10.1038/s41409-020-01165-x. Epub 2020 Dec 5. Bone Marrow Transplant. 2021. PMID: 33279940
Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Schimmer A, McNamara C, Murphy T, Maze D, Gupta V, Sibai H, Chan S, Yee K, Minden M, Zhang Z, Schuh A, Kim DDH. Daher-Reyes G, et al. Bone Marrow Transplant. 2021 Aug;56(8):1908-1918. doi: 10.1038/s41409-021-01255-4. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767401
Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR.
Novitzky-Basso I, Chen C, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Novitzky-Basso I, et al. Eur J Haematol. 2021 Sep;107(3):354-363. doi: 10.1111/ejh.13673. Epub 2021 Jun 14. Eur J Haematol. 2021. PMID: 34076909
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Br J Haematol. 2022 Jan;196(1):136-145. doi: 10.1111/bjh.17807. Epub 2021 Sep 8. Br J Haematol. 2022. PMID: 34496035
The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
Kim DDH, Novitzky Basso I, Kim TS, Yi SY, Kim KH, Murphy T, Chan S, Minden M, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Ng SWK, Stockley T, Zhang T, King I, Mattsson J, Wang JCY. Kim DDH, et al. EJHaem. 2022 May 23;3(3):873-884. doi: 10.1002/jha2.466. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051057 Free PMC article.
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission.
Alfaro Moya T, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, Pasic I, Novitzky-Basso I, Michelis FV. Alfaro Moya T, et al. Eur J Haematol. 2023 Oct;111(4):553-561. doi: 10.1111/ejh.14041. Epub 2023 Jul 18. Eur J Haematol. 2023. PMID: 37461810
49 results